BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) — Aclarion, Inc. (“Aclarion” or the “Company”) (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Special Meeting of Stockholders (the “Special Meeting”) scheduled for February 28, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission (the “SEC”) on February 3, 2025.
The Special Meeting will be reconvened on Wednesday, March 5, 2025, at 9:30 a.m. Mountain Time, and will continue to be held at the Company’s corporate office at 8181 Arista Place, Suite 100, Broomfield, Colorado 80021.
The record date for determination of stockholders entitled to vote at the reconvened Special Meeting remains January 6, 2025. Stockholders as of January 6, 2025, the record date for the Special Meeting, are encouraged to vote as soon as possible.
Proxies previously submitted in respect of the Special Meeting will be voted at the adjourned Special Meeting unless properly revoked. Stockholders who have previously submitted their proxy or otherwise voted and who do …
